ANIMATION

Apoptosis and BCL-2

Share this animation:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO

Client


Abbvie; Genentech

XVIVOs attention to detail and ability to create an engaging, easy to understand story behind this extraordinary product was key to bringing natures generous contribution to life .

Senior Researcher, FrieslandCampina
Share this animation: